Tethys is breaking new ground in the diabetes field with the PreDx DRS, which will help clinicians to identify patients at severe risk of becoming diabetic, and who are most likely to benefit from focused intervention and disease prevention management, said George Rehm, Managing Partner of aeris CAPITAL AG and member of the Tethys Board of Directors. The Company ™s technology has broad utility in multiple chronic disease areas where early identification and disease prevention programs have the potential to improve health outcomes and reduce healthcare costs.

While diabetes has no cure, clinical studies have shown that it can be prevented, and determining one ™s diabetes risk is the first step in avoiding this chronic, life-threatening disease. Clinical studies have shown that aggressive intervention with diet and exercise alone can reduce the incidence of diabetes by up to 60%. With the PreDx Diabetes Risk Score, clinicians can identify those individuals with the greatest 5-year risk of diabetes conversion so they can receive appropriate diabetes prevention regimens.

George M. Rehm is a Managing Partner of aeris CAPITAL AG in Switzerland and has over twenty five years experience as a lawyer and executive in international licensing, technology transfer, investment and privatization transactions, involving the US, Europe and Asia, prior to commencing his current career in private equity. Currently, he holds board seats in numerous portfolio companies. Mr. Rehm remains of counsel to the Munich, Heidelberg and Berlin law firm of Weitnauer Partners. He received his BSFS from Georgetown University, and a JD from the University of California, Hastings College of Law.

Source: Tethys Bioscience